If you are comparing Wegovy and Mounjaro, the first thing to know is that they are not two versions of the same drug. They use different active ingredients, are approved for different conditions, and reach the market under different brand names for weight loss versus diabetes.
This is a clear 2026 breakdown of how Wegovy and Mounjaro compare: what each one is, how they work, the weight loss seen in trials, side effects, cost, and how a physician thinks about the choice.
The Short Answer
Wegovy is semaglutide, FDA-approved for weight loss. Mounjaro is tirzepatide, FDA-approved for type 2 diabetes. They are both once-weekly injections in the GLP-1 family, but Mounjaro acts on a second gut hormone receptor as well.
A key point that confuses many people: the tirzepatide version FDA-approved specifically for weight management is Zepbound, not Mounjaro. Mounjaro and Zepbound are the same active ingredient with different labels. So a weight-loss patient is usually choosing between Wegovy (semaglutide) and Zepbound (tirzepatide), even though people search for "Mounjaro" because it is the better-known name.
Wegovy vs Mounjaro at a Glance
| Feature | Wegovy | Mounjaro |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Drug class | GLP-1 receptor agonist | GIP + GLP-1 receptor agonist |
| FDA-approved for | Chronic weight management | Type 2 diabetes |
| Weight-loss labeled sibling | Wegovy is the weight-loss label | Zepbound (same ingredient) |
| How it is taken | Weekly injection | Weekly injection |
| Average trial weight loss | ~14.9% (STEP-1) | ~20.9% (SURMOUNT-1, tirzepatide) |
| Approx retail price/month | ~$1,349 | ~$1,069 |
| Boxed warning | Thyroid C-cell tumor risk | Thyroid C-cell tumor risk |
Trial percentages come from separate studies and are averages, not guarantees. Individual results vary.
See a lower-cost compounded option
Majesta Health offers doctor-guided GLP-1 plans with transparent monthly pricing, compounded medication, and physician oversight. Take the 2-minute assessment to see if you qualify. No credit card to start.
Compounded medications are not FDA-approved as final products. The active pharmaceutical ingredient meets United States Pharmacopeia (USP) standards. Individual results may vary.
How Each One Works
Both medications mimic gut hormones that your body releases after eating. They slow how fast the stomach empties, signal fullness to the brain, and help regulate blood sugar. The result for most people is reduced appetite and smaller portions without constant hunger.
Wegovy (semaglutide) activates one receptor, the GLP-1 receptor. It is the same molecule as Ozempic, but Wegovy is dosed and labeled for weight management rather than diabetes.
Mounjaro (tirzepatide) activates two receptors, GIP and GLP-1. The addition of GIP is thought to contribute to the larger average weight loss seen in tirzepatide trials, though researchers are still studying exactly why the dual mechanism performs the way it does.
Weight Loss: What the Trials Showed
The headline numbers come from two landmark trials:
On paper, tirzepatide produced more weight loss. But these were separate trials with different participants and designs, not a direct head-to-head comparison, so the gap is not as precise as the numbers suggest. What both trials clearly show is that these medications produce weight loss far beyond what lifestyle change alone typically achieves, and that staying on treatment and titrating properly matters more than the brand on the box.
It is also worth noting that the largest weight loss for most people happens over many months of consistent treatment, not in the first few weeks.
Side Effects Compared
Wegovy and Mounjaro share a similar safety profile because both slow digestion. The most common side effects for both are gastrointestinal:
These are usually mild to moderate and tend to be worst right after a dose increase, which is why prescribers titrate the dose up slowly. Because tirzepatide acts on an extra receptor, some patients find they tolerate one drug better than the other, in either direction.
Both carry a boxed warning about the risk of thyroid C-cell tumors based on animal studies. Neither should be used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2). Both can also, less commonly, be associated with pancreatitis, gallbladder problems, and low blood sugar when combined with certain other medications. Any GLP-1 medication should be taken under the supervision of a licensed clinician who reviews your full history.
For a closer look at how the two ingredients stack up beyond the brand names, see our guide to tirzepatide vs semaglutide.
Cost: Wegovy vs Mounjaro in 2026
At retail without insurance, both are expensive:
Almost nobody pays the full list price. The real cost depends on three things:
1. Insurance coverage. Because Mounjaro is labeled for diabetes and Wegovy for weight loss, plans often cover them differently. Many commercial plans exclude weight-loss drugs or require prior authorization, while diabetes coverage is more common. 2. Manufacturer savings cards. Both Novo Nordisk (Wegovy) and Eli Lilly (Mounjaro) offer savings programs for eligible commercially insured patients that can sharply reduce the copay. 3. Self-pay programs. Manufacturers now sell some doses directly to cash-paying patients at lower prices than the retail pens.
For cash-paying patients focused on weight loss, a common lower-cost route is compounded semaglutide or compounded tirzepatide through a telehealth provider, prepared by a state-licensed compounding pharmacy under an individual prescription. Compounded medications are not FDA-approved as final products, and the active pharmaceutical ingredient meets United States Pharmacopeia (USP) standards. For a full breakdown, see our guides to how much Zepbound costs and compounded tirzepatide cost.
Which One Is Right for You?
There is no single winner. The choice usually comes down to:
The decision is a clinical one. A licensed physician who reviews your history, current medications, and goals is the right person to help you weigh these factors, rather than the trial averages alone.
What Majesta Health Offers
At Majesta Health, we connect patients with US-licensed physicians for doctor-guided GLP-1 treatment, including compounded semaglutide and compounded tirzepatide dispensed by a state-licensed compounding pharmacy, with transparent monthly pricing. Compounded medications are not FDA-approved as final products. The active pharmaceutical ingredient meets United States Pharmacopeia (USP) standards.
This article is general information, not medical advice. A licensed physician reviews your history before prescribing and is the right person to help you choose between semaglutide, tirzepatide, and the specific product that fits your situation. Start your 2-minute medical assessment at /quiz to see if you qualify.
*Related reading:*
Frequently Asked Questions
What is the main difference between Wegovy and Mounjaro?
The main difference is the active ingredient and the approved use. Wegovy is semaglutide, a GLP-1 receptor agonist, and is FDA-approved for chronic weight management. Mounjaro is tirzepatide, which activates two gut hormone receptors (GIP and GLP-1), and is FDA-approved for type 2 diabetes rather than weight loss. Tirzepatide is also sold under the name Zepbound, which is the version FDA-approved specifically for weight management. So a weight-loss patient is more likely to be prescribed Wegovy or Zepbound than Mounjaro itself.
Is Mounjaro or Wegovy better for weight loss?
In clinical trials, tirzepatide (the ingredient in Mounjaro and Zepbound) produced greater average weight loss than semaglutide (the ingredient in Wegovy). In the SURMOUNT-1 trial, participants on the highest tirzepatide dose lost about 20.9 percent of body weight on average, while in the STEP-1 trial semaglutide participants lost about 14.9 percent. These were separate trials, not a head-to-head study, so the numbers are not a perfect comparison. Both produced substantial average weight loss well beyond lifestyle change alone. The right choice depends on your medical history, insurance, tolerability, and your physician's judgment, not on the trial averages alone.
Can you take Mounjaro for weight loss?
Mounjaro is FDA-approved for type 2 diabetes, not for weight loss. Physicians sometimes prescribe it off-label, but the version of tirzepatide FDA-approved specifically for chronic weight management is Zepbound, which contains the same active ingredient. If your goal is weight loss, a clinician is more likely to prescribe Zepbound (tirzepatide) or Wegovy (semaglutide). Coverage and cost often drive which one you end up on.
Do Wegovy and Mounjaro have the same side effects?
They share a similar side-effect profile because both slow digestion. The most common effects for both are gastrointestinal: nausea, diarrhea, constipation, and occasional vomiting, usually most noticeable right after a dose increase. Both carry a boxed warning about the risk of thyroid C-cell tumors based on animal studies and should not be used by people with a personal or family history of medullary thyroid carcinoma or MEN 2. Because tirzepatide acts on an additional receptor, some patients tolerate one better than the other, which is something to discuss with your prescriber.
Is Wegovy or Mounjaro cheaper?
At retail without insurance, both list well over a thousand dollars a month, with Wegovy around $1,349 and Mounjaro around $1,069. Very few people pay full sticker price. Insurance coverage, manufacturer savings cards, and manufacturer self-pay programs change the real cost significantly, and coverage differs because Mounjaro is a diabetes drug while Wegovy is a weight-loss drug. For cash-paying weight-loss patients, compounded semaglutide or compounded tirzepatide through a telehealth provider is often a lower-cost route. Compounded medications are not FDA-approved as final products.
Can you switch from Wegovy to Mounjaro?
Switching between GLP-1 medications is common and is done under a prescriber's guidance, usually restarting at a lower dose and titrating up to limit side effects. Because Wegovy (semaglutide) and Mounjaro or Zepbound (tirzepatide) are different molecules, the dose does not transfer one-to-one. Never switch or adjust on your own. A licensed physician should map the transition based on your current dose, tolerability, and goals.
All Majesta Health medical content is clinically reviewed before publication by US-licensed physicians affiliated with our clinical infrastructure partner. Reviewers hold active state medical licenses, are board-certified in primary care or obesity medicine, and specialize in GLP-1 receptor agonist therapy for chronic weight management. Our clinical partner is LegitScript certified and SOC 2 Type II accredited.
- US-licensed physicians affiliated with our clinical provider group partner (LegitScript certified, HIPAA, SOC 2 Type II, ISO certified)
- Board-certified in primary care and obesity medicine
- Active state medical licensure required for every prescribing clinician
- Active DEA registration where applicable (note: GLP-1 medications are not controlled substances)
- Telehealth practice across all 50 US states and DC through our clinical provider group Medical Services Organization
- Dispensing pharmacy partner: Belmar Pharma Solutions (LegitScript certified, NABP accredited, 503A and 503B compounding)